Low-Dose Cannabinoid Supplement Improved Sleep Quality in a Small Crossover Trial

In a double-blind crossover trial of 20 adults with subthreshold insomnia, a multi-cannabinoid oral supplement (3 mg THC, 6 mg CBN, 10 mg CBD, plus terpenes) significantly improved sleep quality/efficiency, insomnia symptoms, and health-related quality of life compared to placebo after 10 days. Mood and anxiety showed non-significant trends toward improvement. Anxiety improved significantly from baseline for the supplement group. No adverse events were reported.

Randomized, double-blind, placebo-controlled crossover pilot trial. 20 adults with subthreshold insomnia (mean age 47.4) completed 10 days in each condition with a 2-week washout. Validated questionnaires assessed sleep, mood, stress, pain, anxiety, fatigue, and quality of life.

This is one of the few controlled trials testing a low-dose multi-cannabinoid formulation specifically for sleep. The combination of THC, CBN, and CBD at low doses with a terpene blend may offer a more targeted approach than high-dose single-cannabinoid products.

Many cannabis users report using it for sleep, but controlled evidence is limited. Low-dose multi-cannabinoid formulations represent a growing product category that may be more appropriate for sleep than high-THC products.

Very small sample (N=20). Short treatment period (10 days). Self-reported sleep measures without objective polysomnography. Subthreshold insomnia only; may not apply to clinical insomnia. Washout adequacy not verified. Industry-funded study warrants independent replication.